News
Mana Capital Acquisition Corp. and Cardio Diagnostics, Inc. Announce Definitive Business Combination Agreement to Create Publicly Listed Company Set to Transform Cardiovascular Disease Through Epigenetics
Cardio Diagnostics, Inc. has pioneered a proprietary artificial intelligence-driven Integrated Genetic-Epigenetic Engine™ that enables improved diagnosis and prevention of cardiovascular disease The Company’s flagship product, Epi+Gen CHD™, is a highly sensitive and...
Cardio Diagnostics Announces Headquarters Relocation to Chicago
Pioneer of AI-driven, epigenetics-based clinical tests for cardiovascular disease moves for Chicago's thriving biotech ecosystem and access to talent and resources CHICAGO, May 25, 2022 – Cardio Diagnostics, Inc., ("Cardio Diagnostics"), a company pioneering...
Cardio Diagnostics Wins “Clinical Diagnostics Solution of the Year” Award From BioTech Breakthrough
Cardio Diagnostics Wins “Clinical Diagnostics Solution of the Year” Award From BioTech Breakthrough Annual Awards Program Recognizes Innovation in the Global Life Sciences and Biotechnology Industry CHICAGO, October 27, 2021 – Cardio Diagnostics, Inc., a...
Cardio Diagnostics Jan 2021 Press Release
Cardio Diagnostics’ Epi+Gen CHD at-home sampling kit: Potential patients fill out a screening questionnaire that is reviewed by a board-certified clinician. If eligible for the test, a sampling kit is sent to their home. After the sample is collected, it is shipped...
Cardio Diagnostics receives a Phase I NIH SBIR
Cardio Diagnostics received $225K in National Institutes of Health (NIH) funding to further develop our integrated genetic-epigenetic coronary heart disease risk screening technology.
Cardio Diagnostics receives Biotech Innovation Showcase Award
Cardio Diagnostics won the Biotech Innovation Showcase Award and received a $5,000 grand prize at the annual IowaBio Partnering for Growth Conference.